Drugs / Trastuzumab Rezetecan
Trials 21
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 218 trials | ||||||
| Phase 2 | NCT07699952 | Jul 2026 → Mar 2029 expected | non-small cell lung carcinoma | Yongsheng Wang | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07630077 | Jul 2026 → Jul 2027 expected | non-small cell lung carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07631884 | Jun 2026 → Dec 2028 expected | biliary tract neoplasm, colorectal neoplasm, endometrium neoplasm, gastric neoplasm +5 | Haihua Yuan | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07639983 | Jun 2026 → Jun 2028 expected | infiltrating bladder urothelial carcinoma | Sheng Tai | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07624201 | Jun 2026 → Jun 2028 expected | urinary bladder carcinoma | Harbin Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07630103 | Jun 2026 → Jun 2031 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07670273 | Apr 2026 → Apr 2027 expected | biliary tract cancer | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07497386 | Apr 2026 → Jun 2028 expected | breast carcinoma | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07704177 | Apr 2026 → Apr 2027 expected | biliary tract neoplasm | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07647263 | Mar 2026 → Jun 2029 expected | HER2 positive breast carcinoma | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT07203729 | Mar 2026 → Jun 2030 expected | breast cancer | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT07416253 | Mar 2026 → Mar 2027 expected | breast cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07383818 | Feb 2026 → Feb 2028 expected | hormone receptor-positive breast cancer | First Affiliated Hospital of Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT07241793 | Nov 2025 → Jul 2028 expected | urothelial carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07129018 | Nov 2025 → Nov 2027 expected | biliary tract cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07179939 | Sep 2025 → Dec 2030 expected | HER2 positive breast carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07037199 | Aug 2025 → Jun 2028 expected | breast cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT07047755 | Jul 2025 → Jul 2026 overdue | breast cancer | Henan Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07679360 | Jul 2026 → Dec 2030 expected | triple-negative breast carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07600164 | Jul 2026 → Dec 2031 expected | HER2 positive breast carcinoma | Peking University People's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07589699 | May 2026 → Dec 2028 expected | HER2 positive breast carcinoma | The First Affiliated Hospital with Nanjing Medical University | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT07100600 Background | Aug 2025 → Jul 2030 expected | HER2 positive breast carcinoma, metastatic malignant neoplasm in the brain | Henan Cancer Hospital | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2026-07-02 | Glenmark Pharmaceuticals Ltd. India | Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer glenmarkpharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Trastuzumab-rezetecan | “A Randomized, Open-Label, Phase II Study Comparing the Efficacy and Safety of Trastuzumab-rezetecan and Trastuzumab Deruxtecan (T-DXd) in Neoadjuvant Treatment of Patients With...” NCT07416253 ↗22“EGFR-TKI combined with Trastuzumab Rezetecan(HER2 ADC)” NCT07699952 ↗ |
| Known as | SHR-A1811 | “Trastuzumab Rezetecan (SHR-A1811) Versus Chemotherapy of Physician's Choice in Patients With HER2-Low Unresectable/Metastatic Breast Cancer Complicated With Visceral Crisis：A...” NCT07203729 ↗2“Trastuzumab Rezetecan (SHR-A1811) combined with ivonescimab (AK112)” NCT07630077 ↗ “Trastuzumab Rezetecan (SHR-A1811)” NCT07647263 ↗ |
| Modality | Monoclonal antibody | “humanized HER2-targeting monoclonal antibody” NCT07589699 ↗ |
| Route | Intravenous | “Trastuzumab-rezetecan (4.8 mg/kg, iv, d1, q3w)” NCT07129018 ↗ |